Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity.

Biomed Res Int · 2013 · PMC3625605 · PMID 23607088

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Higher on-clopidogrel platelet reactivity was observed as the number of CYP2C19 LOF allele increased (UM 4.0; EM, 177.7; IM, 201.7; and PM 277.0), but post hoc analysis did not reach statistical significance for linear trend, probably as a result of the small number of patients.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.